TyraTech, Inc. New Anti-Endoparasitic Composition Patents (9520U)
January 07 2013 - 4:40AM
UK Regulatory
TIDMTYR TIDMTYRU
RNS Number : 9520U
TyraTech, Inc.
07 January 2013
7 January 2013
TyraTech, Inc.
(the "Company" or "TyraTech")
New Anti-Endoparasitic Composition Patents for Human and Animal
Health
Patents Protect New Human and Animal Health Anthelmintic
Pipeline Products
TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences
company, is pleased to announce that the Company has received
notices, from both the United States Patent and Trademark Office
and the State Intellectual Property Office of the People's Republic
of China, granting two new patents for the Company's novel natural
compositions for controlling intestinal worms and parasites.
The World Health Organization estimates that over 2 billion
people suffer from intestinal parasite infections with more than
half of these incidences being found in children between the ages
of 7 and 14 years. The infections can result in debilitating
conditions such as malnutrition, anemia, immune suppression and
delayed intellectual development in children.
In animals, intestinal parasites have a significant impact on
both productivity and wellbeing. In addition, companion animals in
particular, have the potential to transmit parasites on to
humans.
The Directors of the Company believe that these new patents are
an important addition to TyraTech's intellectual property portfolio
as they will provide support and protection of the Company's
pipeline of anthelmintic solutions for humans, as well as companion
and production animals.
The issuance of these patents increases TyraTech's patent
portfolio to a current total of fourteen United States and
international patents protecting its proprietary screening platform
and compositions.
Alan Reade, Executive Chairman of the Company said:
"These new patents further confirm TyraTech as an innovative
human and animal health company. We believe that these additional
patents will help the Company create an array of exciting
opportunities in the human and animal health markets.
"Additionally, the expansion of our IP portfolio validates our
position at the forefront of developing best-in-class solutions
capable of delivering the highest levels of efficacy and safety for
people, pets, and production animals. Intestinal parasite
infections have a very negative impact on millions of young people
in many areas of the world. TyraTech is therefore particularly
satisfied to have the opportunity to commercialise a very safe and
effective solution to a significant public health issue."
For further information please contact:
TyraTech Inc.
Alan Reade, Executive Chairman
Tel: +1 919 415 4310
Peter Jerome, Chief Financial Officer
Tel: +1 919 415 4280
N+1 Singer, Nominated Adviser and Joint Broker
Aubrey Powell / Alex Wright
Tel: +44 20 7496 3000
First Columbus LLP, Joint Broker
Chris Crawford
Tel: +44 20 3002 2070
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBGGDBXXGBGXR
Tyratech (LSE:TYR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tyratech (LSE:TYR)
Historical Stock Chart
From Jul 2023 to Jul 2024